ÂÜŔňÂŇÂ×

Dr. Antony Loebel is President and CEO of Sunovion Pharmaceuticals Inc., a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions.

Sunovion’s track record of discovery, development and commercialization of important psychiatric, neurological and respiratory therapies has included Latuda® (lurasidone HCl), Brovana® (arformoterol tartrate), Aptiom® (eslicarbazepine acetate) and Lonhala® Magnair® (glycopyrrolate) Inhalation Solution and, most recently, KYNMOBI™ (apomorphine HCl) sublingual film.

Dr. Loebel joined the Company in 2007. His prior industry experience includes seven years in drug development and medical affairs roles at Pfizer. He serves as an Executive Leadership Team member of Sunovion and an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd., the parent company of Sunovion. Dr. Loebel also serves on the Pharmaceutical Research and Manufacturers of America (PhRMA) Board of Directors and previously served on the Massachusetts Biotechnology Council (MassBio) Board of Directors.

During his tenure at Sunovion, Dr. Loebel has provided strategic direction and leadership of Research & Development (R&D), including overseeing the Global Clinical Development organization. In this role, he directed initiatives designed to improve global R&D operational efficiency and to address unmet medical needs through innovation in drug development. Dr. Loebel’s scientific work has led to the publication of numerous articles on the diagnosis and treatment of severe mental illness.